Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration.

@article{Hopewell1992EvaluationON,
  title={Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration.},
  author={P. Hopewell and Michael Cynamon and Jeffrey Starke and Michael F Iseman and Rick O'Brien},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={1992},
  volume={15 Suppl 1},
  pages={S282-95}
}
This guideline addresses the evaluation of new antimycobacterial drugs in the treatment and prevention (secondary prophylaxis) of infection by M. tuberculosis. Patients may be enrolled in clinical trials on the basis of clinical and/or microbiological criteria. A therapeutic regimen will likely include a combination of drugs; a randomized, active-control, comparative clinical trial is recommended. If appropriate samples can be obtained for culture during follow-up without placing the patient at… CONTINUE READING